Faster recovery. Easier fat loss. Younger-looking skin. Peptides are being promoted for a growing list of health and wellness goals. But how much of the promise is supported by evidence?
In Australia, unapproved peptide products are being marketed through online sellers, influencers and wellness clinics, with claims around recovery, muscle growth, fat loss and anti-ageing.[1]
The appeal is understandable. Injuries are frustrating, recovery takes time, and a shortcut can sound convincing. Before accepting the promise, though, it helps to understand what these products are, what has actually been tested and what remains unknown.
What are peptides?
Peptides are short chains of amino acids, the building blocks that also make up proteins. They occur naturally in the body and participate in many biological processes.[1]
Some peptide-based medicines have established medical uses. Insulin and certain GLP-1 medicines are examples approved in Australia for specific therapeutic purposes.[2]
But “peptide” describes a type of molecule. It does not establish that a product is safe, effective or suitable for a particular health goal.
The success of an approved peptide medicine cannot be used as evidence that a different compound sold for recovery or longevity works.
Why does the marketing sound convincing?
Peptide promotions often refer to processes such as tissue repair, hormone signalling and blood vessel formation. Researchers have investigated biological mechanisms like these in studies of substances including BPC-157.[4]
However, explaining how a substance might act is different from showing that it produces a meaningful benefit in people.
Laboratory and animal studies can identify possibilities worth investigating. They cannot, on their own, establish that a treatment works safely in humans.
Testimonials have limitations too. Someone feeling better after a treatment does not establish what caused the improvement, whether others would benefit or what risks might emerge over time.
The useful question is not simply “does it sound scientific?” It is “what does the human evidence actually show?”
Do recovery peptides work?
The answer depends on the exact substance and the claimed benefit. For several widely promoted products, reliable human evidence remains limited.
BPC-157
BPC-157 is frequently discussed in relation to injury recovery. Some human research exists, including a small retrospective study of patients who received knee injections containing BPC-157, either alone or combined with thymosin beta-4.[3]
A retrospective study looks back at treatment already received. Without a suitable comparison group, it cannot reliably distinguish a treatment effect from natural improvement, other treatments or differences between patients.
In its 2026 assessment, the US Food and Drug Administration identified small, short-duration human studies involving different conditions and administration routes. It highlighted limited safety reporting and uncertainty about safety monitoring.[4]
These findings do not establish BPC-157 as a safe and effective treatment for injury recovery. A study suggesting possible benefit is a reason for better research, rather than a guarantee that a marketed product works.
TB-500
TB-500 is often promoted alongside BPC-157. In its 2026 assessment of TB-500 free base and acetate, the FDA did not identify human clinical studies supporting their proposed use for wound healing.[5]
The assessment also distinguished these substances from the larger thymosin beta-4 molecule. Research on thymosin beta-4 should not automatically be treated as evidence for the TB-500 substances reviewed.[5]
The exact molecule matters. Similar names do not make treatments interchangeable.
Other wellness peptides
For substances including CJC-1295, ipamorelin and injectable GHK-Cu, the FDA has identified limited safety information and concerns involving possible immune reactions or peptide-related impurities. It has also identified serious adverse events associated with CJC-1295, including increased heart rate.[6]
These concerns differ between substances and administration routes. They should not be interpreted as evidence that all peptides carry identical risks.
What are the risks?
There are two separate questions: what the substance does to the body, and whether the supplied product contains what it claims.
In June 2026, the TGA and Australia’s Chief Medical Officer issued a joint warning about unapproved peptide products. Reports had identified serious adverse effects including liver damage, severe allergic reactions requiring hospitalisation, and inflammation or other complications requiring medical attention.[7]
These reports concern unapproved products collectively. They do not establish that every named peptide causes every listed harm.
The warning also highlighted uncertainty about ingredients, manufacturing standards, dosing and whether injectable products are sterile. Poorly labelled or unmarked vials can make it difficult to verify what a person is receiving.[7]
A polished website or reassuring testimonial cannot resolve those uncertainties. Even a potentially useful substance can present risks when its identity, strength or quality is unreliable.
Are these products approved in Australia?
Some peptide-based medicines are approved for specific medical purposes. Many peptide products promoted for wellness, recovery and anti-ageing are not included in the Australian Register of Therapeutic Goods.[2]
Therapeutic peptide products generally need to be included in the register before they can be imported, manufactured or supplied, unless a valid exemption, approval or authority applies. Unapproved products have not been assessed by the TGA for quality, safety or effectiveness.[2]
There are limited lawful pathways through which clinicians may access unapproved products for individual patients. However, a prescription or compounded preparation does not itself make a product TGA-approved.[1,8]
The TGA says applications for access should be supported by human studies relevant to the specific peptide, formulation, administration route and medical condition.[8]
A “research use only” label does not remove therapeutic goods obligations. The TGA explicitly states that these disclaimers do not change whether a product is regulated as a therapeutic good.[2]
What is happening overseas?
The US is also examining peptides used in pharmacy compounding. The FDA’s July 2026 advisory committee meeting considered substances including BPC-157, TB-500 and MOTS-c.[9]
A review of substances for compounding is separate from approval of a finished medicine. The FDA’s briefing documents explain that the advisory process informs its assessment rather than constituting a final determination.[4,5]
Debate about access does not demonstrate that a treatment works for recovery or longevity. Nor does a US regulatory process determine Australian approval status.
The relevant questions remain the same: what was tested, in whom, for which outcome, and with what risks?
What about collagen peptides?
You may have noticed the word “peptides” on your collagen powder too. This is where the terminology can get confusing.
Chief’s Collagen Protein Powder contains grass-fed bovine collagen peptides. “Hydrolysed” means the collagen protein has been broken down into smaller chains called peptides.[10]
It is an oral nutrition product, rather than an injectable compound marketed as a medical treatment for injury recovery or longevity. Sharing the word “peptide” does not make these products interchangeable.
The same principle applies throughout this discussion: assess the exact ingredient, product and claimed benefit. Evidence for one peptide cannot be borrowed to support another. Equally, warnings about particular unapproved injections should not automatically be applied to collagen powders.
What if you compete in sport?
Many peptides, including BPC-157, CJC-1295 and ipamorelin, are prohibited in sport. Sport Integrity Australia warns that possession or use can result in anti-doping violations and potential bans.[1]
A prescription does not automatically protect an athlete from those consequences. Athletes should check the status of the exact substance and applicable therapeutic use exemption requirements.[1]
What should we take from the hype?
Wanting better health is reasonable. Expecting evidence before accepting a health claim is reasonable too.
Limited evidence does not prove that a substance could never become a useful treatment. It does mean that confident marketing may be ahead of what has been established.
Before accepting a peptide promise, ask:
- Is there reliable human evidence for this exact substance and claimed benefit?
- Was the same formulation and administration route studied?
- What is known about side effects and longer-term safety?
- Has the product been assessed by the relevant regulator?
- Can its ingredients, dose and manufacturing quality be verified?
Real food, daily routines and appropriate care for injuries may make a less exciting sales pitch. But the appeal of something new should not lower the standard of evidence we expect.
A big promise deserves more than a testimonial.
This article provides general education and does not recommend unapproved peptide products or replace individual medical advice. Research and regulatory information checked on 12 October 2026.
References
- Sport Integrity Australia. Peptides explained. Peptide basics, wellness promotion, quality concerns and anti-doping requirements.
- Therapeutic Goods Administration. How we regulate therapeutic peptide products. Approved medicines, Australian regulatory requirements and research-use disclaimers.
- Lee E, Padgett B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 27(4), 8–13. PMID: 34324435.
- US Food and Drug Administration. (2026). BPC-157-related bulk drug substances: briefing document. Pharmacy Compounding Advisory Committee, July 23–24. Human studies, evidence limitations and safety assessment.
- US Food and Drug Administration. (2026). TB-500-related bulk drug substances: briefing document. Pharmacy Compounding Advisory Committee, July 23–24. Substance identity, wound-healing evidence and safety gaps.
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Substance-specific safety concerns.
- Therapeutic Goods Administration and Australia’s Chief Medical Officer. (19 June 2026). Concerns regarding the public health risks associated with unapproved peptide products. Reported adverse effects and uncertainties about product quality.
- Therapeutic Goods Administration. Peptide product information for health practitioners. Clinical access pathways and requirements for relevant human evidence.
- US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Substances considered in the US compounding review.
- Chief Nutrition. What type of collagen do you use in your powders? and Collagen Protein Powder. Product composition and explanation of hydrolysed collagen peptides.
